134 related articles for article (PubMed ID: 26997452)
21. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
[TBL] [Abstract][Full Text] [Related]
22. [Place of the pathologist in the management of primary bone tumors (osteosarcoma and Ewing's family tumors after neoadjuvant treatment)].
Gomez-Brouchet A; Bouvier C; Decouvelaere AV; Larousserie F; Aubert S; Leroy X; Guinebretière JM; Coulomb A; Cassagnau E; de Muret A; Audard V; Marie B; de Pinieux G
Ann Pathol; 2011 Dec; 31(6):455-65. PubMed ID: 22172118
[TBL] [Abstract][Full Text] [Related]
23. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome.
Baldini N; Scotlandi K; Barbanti-Bròdano G; Manara MC; Maurici D; Bacci G; Bertoni F; Picci P; Sottili S; Campanacci M
N Engl J Med; 1995 Nov; 333(21):1380-5. PubMed ID: 7477118
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
Pathol Res Pract; 1998; 194(10):679-84. PubMed ID: 9820863
[TBL] [Abstract][Full Text] [Related]
25. P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis.
Bu J; Li H; Liu LH; Ouyang YR; Guo HB; Li XY; Xiao T
Int J Clin Exp Pathol; 2014; 7(9):6091-6. PubMed ID: 25337256
[TBL] [Abstract][Full Text] [Related]
26. Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas.
Maitra A; Roberts H; Weinberg AG; Geradts J
Int J Cancer; 2001 Jan; 95(1):34-8. PubMed ID: 11241308
[TBL] [Abstract][Full Text] [Related]
27. Cell Cycle Checkpoints p16 and p21-Strong Predictors of Clinicopathologic Outcomes in High-Grade Osteosarcoma.
Nasri E; Torrence DE; Vasilopoulos T; Knapik JA; Lagmay JP; Reith JD; Gibbs CP
Cancer J; 2024 May-Jun 01; 30(3):133-139. PubMed ID: 38753746
[TBL] [Abstract][Full Text] [Related]
28. Examination of the cutoff value of postchemotherapy increase in tumor volume as a predictor of subsequent oncologic events in stage IIB osteosarcoma.
Jeon DG; Kong CB; Cho WH; Song WS; Cho SH; Choi SW; Lee SY
J Surg Oncol; 2014 Mar; 109(3):275-9. PubMed ID: 24243222
[TBL] [Abstract][Full Text] [Related]
29. Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases.
Bacci G; Ferrari S; Ruggieri P; Biagini R; Fabbri N; Campanacci L; Bacchini P; Longhi A; Forni C; Bertoni F
Acta Orthop Scand; 2001 Apr; 72(2):167-72. PubMed ID: 11372948
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome.
Kersting C; Gebert C; Agelopoulos K; Schmidt H; van Diest PJ; Juergens H; Winkelmann W; Kevric M; Gosheger G; Brandt B; Bielack S; Buerger H
Clin Cancer Res; 2007 May; 13(10):2998-3005. PubMed ID: 17505002
[TBL] [Abstract][Full Text] [Related]
31. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
Nielsen GP; Burns KL; Rosenberg AE; Louis DN
Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
[TBL] [Abstract][Full Text] [Related]
32. Tumour response of osteosarcoma to neoadjuvant chemotherapy evaluated by magnetic resonance imaging as prognostic factor for outcome.
Laux CJ; Berzaczy G; Weber M; Lang S; Dominkus M; Windhager R; Nöbauer-Huhmann IM; Funovics PT
Int Orthop; 2015 Jan; 39(1):97-104. PubMed ID: 25432323
[TBL] [Abstract][Full Text] [Related]
33. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
[TBL] [Abstract][Full Text] [Related]
34. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
Ann Surg Oncol; 2008 Mar; 15(3):906-14. PubMed ID: 18163171
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.
Rossi B; Schinzari G; Maccauro G; Scaramuzzo L; Signorelli D; Rosa MA; Fabbriciani C; Carlo B
BMC Musculoskelet Disord; 2010 Feb; 11():34. PubMed ID: 20158913
[TBL] [Abstract][Full Text] [Related]
36. Does expression of glucose transporter protein-1 relate to prognosis and angiogenesis in osteosarcoma?
Kubo T; Shimose S; Fujimori J; Furuta T; Arihiro K; Ochi M
Clin Orthop Relat Res; 2015 Jan; 473(1):305-10. PubMed ID: 25193692
[TBL] [Abstract][Full Text] [Related]
37. Osteosarcomas after the age of 50: a clinicopathologic study of 64 cases--an experience in northern Japan.
Okada K; Hasegawa T; Nishida J; Ogose A; Tajino T; Osanai T; Yanagisawa M; Hatori M
Ann Surg Oncol; 2004 Nov; 11(11):998-1004. PubMed ID: 15525829
[TBL] [Abstract][Full Text] [Related]
38. Spontaneous necrosis in osteosarcoma.
Springfield DS; Schakel ME; Spanier SS
Clin Orthop Relat Res; 1991 Feb; (263):233-7. PubMed ID: 1993380
[TBL] [Abstract][Full Text] [Related]
39. Noninvasive assessment of response to neoadjuvant chemotherapy in osteosarcoma of long bones with diffusion-weighted imaging: an initial in vivo study.
Wang CS; Du LJ; Si MJ; Yin QH; Chen L; Shu M; Yuan F; Fei XC; Ding XY
PLoS One; 2013; 8(8):e72679. PubMed ID: 23991141
[TBL] [Abstract][Full Text] [Related]
40. Correlation between fluid-fluid levels on initial MRI and the response to chemotherapy in stage IIb osteosarcoma.
Jeon DG; Cho WH; Song WS; Kong CB; Cho SH; Lee JW; Lee SY
Ann Surg Oncol; 2014 Jun; 21(6):1956-62. PubMed ID: 24577812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
